Skip to content
Translational Neuropharmacology Lab (Zanos Lab)

Translational Neuropharmacology Lab (Zanos Lab)

Our laboratory, based in Cyprus, employs molecular and systems neuroscience, behavioral pharmacology, as well as advanced computational methods to unravel the mysteries of brain diseases and identify targets for the development of novel and effective pharmacotherapies.

Menu
  • Home
  • News
  • Team Members
    • Lab Director
    • Current Team Members
    • Alumni
  • Research
  • Research Units
    • Translational Neuropharmacology Unit
    • Clinical Neuropsychopharmacology Unit
    • AI & Systems Bioinformatics Unit Cyprus
    • Genetic Epidemiology Unit
  • Facilities
  • Publications
  • Media
  • Join Us
  • Contact
  • More

Category: News

News

Gut-Brain connections: Dr. Charalambous presents groundbreaking research on phageome and brain ageing at Grainau workshop

No Comments
| News

Our postdoctoral researcher Eleftheria Charalambous presented our latest findings at the 12th Grainau Workshop of Genetic Epidemiology in Grainau, Germany. With her talk “The gut phageome is associated with brain ageing” she sparked insightful conversations with other researchers. Dr. Charalambous studies the link between bacteriophages in the gut microbiome and the brain. Bacteriophages are viruses […]

Read More »

Dr. Zanos was invited as an expert to give an interview and answer critical question about depression and its underlying mechanisms by a groundbreaking European-funded initiative.

No Comments
| News

Dr. Zanos was invited as an expert contributor to the “TO AITION” project’s Q&A section. “TO AITION” is a groundbreaking EU-funded project investigating the complex relationship between cardiovascular disease (CVD) and depression, aiming to uncover underlying mechanisms and develop novel tools for prevention, diagnosis, and treatment. In this role, Dr. Zanos addressed critical questions about […]

Read More »

Dr. Zanos discusses drug addiction on the satellite television channel of the Cyprus Broadcasting Corporation (RIK 1).

No Comments
| News

We are thrilled to share that Dr. Panos Zanos was invited to appear on RIK Sat, the satellite television channel of the Cyprus Broadcasting Corporation (CyBC), to discuss the critical issue of drug addiction. This invitation from RIK Sat, one of Cyprus’s premier broadcasting platforms, underscores the significance of Dr. Zanos’ work in the field […]

Read More »

New Preprint: Network-Based Analysis Identifies Targetable Pathways in Comorbid Type II Diabetes and Neuropsychiatric Disorders.

No Comments
| News

We are pleased to announce the release of a new preprint from Dr. Anna Onisiforou and Dr. Panos Zanos, titled “Network-Based Analysis Identifies Targetable Pathways in Comorbid Type II Diabetes and Neuropsychiatric Disorders.” This preprint is available on bioRxiv and represents a significant step forward in understanding the complex interactions between Type 2 Diabetes Mellitus […]

Read More »

Dr. Zanos Speaks on Neurobiology of Drug Addiction at Substance Use Disorders Awareness Event in Cyprus

No Comments
| News

We are excited to share that Dr. Zanos was invited by OFSEAK Cyprus and the Cyprus Anti-Cancer Society to deliver a keynote address on the neurobiology of drug addiction at a recent Substance Use Disorders Awareness event. This notable event took place in Cyprus and was covered extensively by several television outlets. Dr. Zanos’s presentation […]

Read More »

New Publication: Molecular Signatures of Premature Aging in Major Depression and Substance Use Disorders.

No Comments
| News

We are excited to announce the latest publication from our talented Research Associate and Head of the Bioinformatics Unit, Dr. Anna Onisiforou, in collaboration with Dr. Polymnia Georgiou. Their groundbreaking paper, titled “Molecular signatures of premature aging in Major Depression and Substance Use Disorders,” has been published in Scientific Data (Nature Group). Major depressive disorder (MDD) and […]

Read More »

Our postdoctoral researcher, Dr. Eleftheria Charalambous, presented our latest findings at the 10th International Human Microbiome Consortium (IHMC) Congress 2024

No Comments
| News

Her presentation, titled “The gut phageome is associated with healthy brain ageing” drew significant interest from fellow researchers. Dr. Charalambous’s work explores the connection between bacteriophages in the gut microbiome and cognitive health as we age. Her research suggests that the makeup and variety of the gut phageome may play an important role in maintaining […]

Read More »

Dr. Zanos discusses the path to alcohol dependence on a TV program (watch @57:40 min).

No Comments
| News

Dr. Zanos was recently invited to speak on a TV channel about the neurobiology of alcohol addiction, where he explored the complex processes that lead from casual alcohol use to full-blown dependence. Initially, alcohol consumption often presents an aversive taste; however, this negative experience is quickly overshadowed by the activation of the brain’s reward system. […]

Read More »

Our new chapter entitled “Neuroendocrine Regulation of Anxiety” is now out in book: Anxiety Disorders and Related Conditions.

No Comments
| News

Our latest book chapter delves into the complex interactions between the central nervous system and endocrine signals, highlighting their crucial role in shaping emotional processing and behaviors related to anxiety. While the hypothalamic-pituitary-adrenal (HPA) axis has traditionally been the focal point, this chapter expands the discussion to include various steroid and peptide hormones that are […]

Read More »

Dr. Zanos was invited to present data on GluN2AR-dependent antidepressant actions of ketamine and other putative antidepressants at the CINP conference

No Comments
| News

Dr. Zanos recently presented our latest research on the antidepressant actions of ketamine and other potential antidepressants at the European University of Cyprus. His talk focused on the role of NMDA receptor (NMDAR) activation in the rapid antidepressant effects of these compounds. Contrary to the traditional view of ketamine as an NMDAR antagonist, our findings […]

Read More »

Posts pagination

Previous 1 … 9 10 11 … 13 Next

Recent Posts

  • Research spotlight: Unraveling the role of Eukaryotic Elongation Factor 2 Kinase in the antidepressant mechanism of (2R,6R)-hydroxynorketamine June 4, 2026
  • Research spotlight: Alexithymia and emotion regulation across smoking status groups May 26, 2026
  • New manuscript: The Immunosuppression Paradox in Multiple Sclerosis: Are We Fueling the Fire by Suppressing Immunity in an Epstein–Barr Virus–Linked Disease? March 12, 2026
  • New Preprint article – From Heatwaves to Brainwaves: Climate-Driven Microplastics Promote Epstein–Barr Virus Reactivation and Female-Biased Risk for Alzheimer’s Disease and Multiple Sclerosis February 24, 2026
  • New Publication – Linking Misophonia and Tinnitus: Common and Divergent Neurobiological Mechanisms January 29, 2026

Navigation

  • Home
  • News
  • Team Members
    • Lab Director
    • Current Team Members
    • Alumni
  • Research
  • Research Units
    • Translational Neuropharmacology Unit
    • Clinical Neuropsychopharmacology Unit
    • AI & Systems Bioinformatics Unit Cyprus
    • Genetic Epidemiology Unit
  • Facilities
  • Publications
  • Media
  • Join Us
  • Contact
  • More

Translational Neuropharmacology Lab (Zanos Lab) 2026 . Powered by WordPress